ID: ALA5220239

Max Phase: Preclinical

Molecular Formula: C19H19N5O3S

Molecular Weight: 397.46

Representations

Canonical SMILES:  O=C(Nc1c2c(cc3c1CCC3)CCC2)NS(=O)(=O)c1cnn2cccnc12

Standard InChI:  InChI=1S/C19H19N5O3S/c25-19(23-28(26,27)16-11-21-24-9-3-8-20-18(16)24)22-17-14-6-1-4-12(14)10-13-5-2-7-15(13)17/h3,8-11H,1-2,4-7H2,(H2,22,23,25)

Standard InChI Key:  IYYACBQJFQUPTP-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 397.46

Molecular Weight (Monoisotopic): 397.1209

AlogP: 2.22

#Rotatable Bonds: 3

Polar Surface Area: 105.46

Molecular Species: ACID

HBA: 6

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 5.20

CX Basic pKa:

CX LogP: 3.17

CX LogD: 2.25

Aromatic Rings: 3

Heavy Atoms: 28

QED Weighted: 0.70

Np Likeness Score: -1.41

References

1. McBride C, Trzoss L, Povero D, Lazic M, Ambrus-Aikelin G, Santini A, Pranadinata R, Bain G, Stansfield R, Stafford JA, Veal J, Takahashi R, Ly J, Chen S, Liu L, Nespi M, Blake R, Katewa A, Kleinheinz T, Sujatha-Bhaskar S, Ramamoorthi N, Sims J, McKenzie B, Chen M, Ultsch M, Johnson M, Murray J, Ciferri C, Staben ST, Townsend MJ, Stivala CE..  (2022)  Overcoming Preclinical Safety Obstacles to Discover (S)-N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-6-(methylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide (GDC-2394): A Potent and Selective NLRP3 Inhibitor.,  65  (21.0): [PMID:36279149] [10.1021/acs.jmedchem.2c01250]

Source

Source(1):

• Scientific Literature